Connect with us

Technology

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics’ Single Cell Genomics Sequencing Technology

Published

1 year ago

on

Gene structure information identified by combining Compugen’s AI/ML predictive computational discovery platform, Unigen™ with Ultima’s UG 100™ sequencing platform to better understand tumor biology and immune regulationLeveraging Compugen’s computational analytical tools uncovered high consistency in single-cell expression levels across Ultima’s UG 100 sequencing platform, offering a potential advantage for demarcation of transcript termination.Research presented at Advances in Genome Biology and Technology (AGBT) 2025 General Meeting

HOLON, Israel, Feb. 26, 2025 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced results generated in a joint research collaboration, combining Compugen’s AI/ML powered predictive computational discovery platform, Unigen, with high throughput single cell sequencing on Ultima’s UG 100 to uncover new insights on gene structure for immuno-oncology.

“We are excited to collaborate with Ultima Genomics, a pioneer in next generation gene sequencing, to enhance our proprietary gene sequencing database, which is part of our Unigen platform,” said Eran Ophir, Ph.D., Chief Scientific Officer at Compugen. “We developed algorithms to study gene splicing in single cell resolution and applied it to analyze patient tumor samples to uncover new potential regulatory mechanisms in immuno-oncology. Some of the findings were presented at the AGBT conference. Compugen plans to further harness Ultima’s technology to develop its proprietary single cell atlases for accelerated discovery of new immunotherapies.”

“We are excited to support Compugen’s capabilities in predictive computational discovery of new drug targets and development of new cancer immunotherapies,” said Gilad Almogy, Founder and CEO of Ultima Genomics. “We built our innovative sequencing architecture and our UG 100 sequencing platform to enable researchers to unlock new applications and insights through lower cost sequencing and more omics data. The successful outcome of our collaboration with Compugen is a great example of an application that is data-starved due to the constraints of conventional sequencing technology and can be transformed through large scale data and AI/ML techniques. Single cell sequencing is also an excellent fit for our technology which is now compatible with the leading library prep technologies.”

Dr. Roy Granit, Head of Computational Discovery at Compugen is the lead author on a poster presented by Ultima Genomics at the Advances in Genome Biology and Technology (AGBT) 2025 general meeting on February 25, 2025, in Marco Island, Florida. 

Poster presentation details:

Title: Using 3′ Single Cell Sequencing to Study Patient-Derived Tumor Cells Reveals Enhanced Potential to Study Differential Splicing at the Cell Type Level
Poster number: 224
Date and time: Tuesday, February 25, 4:45 p.m. – 6:10 p.m. ET
Leading author: Roy Granit, Ph.D., Director, Head of Computational Discovery, Compugen, Israel
Presenter: Zohar Shipony, Ph.D. Ultima Genomics, United States

Key Findings:

Comparative analysis using tumor samples from cancer patients, found high consistency in single-cell expression levels across Ultima Genomics’ UG 100 and Illumina’s Novaseq 6000 sequencing platforms.UG 100 offers clearer demarcation of 3′ mRNA transcript end and provides a unique opportunity to study gene structure, which can potentially be harnessed to better understand tumor biology and immune regulation. Gene structure information identified in this approach is contributing to the predictive models of Unigen.

The poster is available on the publications section of Compugen’s website, www.cgen.com.

About Unigen™

Compugen has been at the forefront of decoding cancer biology, with its AI/ML powered predictive computational discovery platform, recently branded as Unigen™. Unigen is Compugen’s code-to-cure, flexible-loop platform for the computational prediction of novel drug target discovery and development of cancer immunotherapy. Unigen combines Compugen’s deep scientific knowledge, AI/ML predictive algorithms and a cloud-based, technology-agnostic platform integrating a variety of biological data such as multi-omics, single-cell RNA sequencing and spatial omics data. The outcomes from Compugen’s preclinical and clinical trials enrich the proprietary knowledgebase to discover additional novel drug targets and further understand complex biology. To date, Unigen has yielded multiple novel immuno-oncology drug targets, potential first- or best-in-class clinical stage immuno-oncology programs, validating partnerships with multiple pharmaceutical companies and undisclosed programs in its early-stage pipeline.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” “potential,” “plan,” “goal,” “estimate,” “likely,” “should,” “confident,” and “intends,” and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statement regarding Ultima’s UG 100™ sequencing platform offering a potential advantage for demarcation of transcript termination and statements regarding Compugen’s plans to further harness Ultima’s technology to develop its proprietary single cell atlases for accelerated discovery of new immunotherapies. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: the clinical trials of any product candidates that Compugen, or any current or future collaborators, may develop may fail to satisfactorily demonstrate safety and efficacy to the FDA, and Compugen, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates; Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen’s approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; general market, political and economic conditions in the countries in which Compugen operates, including Israel; the effect of the evolving nature of the recent war in Gaza; and Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value. These risks and other risks are more fully discussed in the “Risk Factors” section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Compugen contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

 

View original content:https://www.prnewswire.com/news-releases/compugen-enhances-its-aiml-predictive-computational-discovery-platform-unigen-with-ultima-genomics-single-cell-genomics-sequencing-technology-302385891.html

SOURCE Compugen Ltd.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Quintus Flexform™ Press Enables Sona SPEED to Deliver Flight-Critical Aerospace Components Faster

Published

5 minutes ago

on

April 22, 2026

By

Advanced forming technology strengthens precision manufacturing capabilities and reduces lead times for global high-performance industries

VÄSTERÅS, Sweden, April 22, 2026 /PRNewswire-PRWeb/ — Sona SPEED Pvt. Ltd., a specialist in precision mechatronics manufacturing solutions, is investing in a Quintus Flexform™ fluid cell press to expand its capabilities in producing high-precision prototype and low-volume components for aerospace and other demanding industries. The new press will support the company’s growing role as a supplier of flight-critical components for global customers.

Quintus Technologies’ expertise in high-pressure forming solutions meets the strict standards required for aerospace applications, enabling us to deliver consistent quality, performance, and reliability to customers operating in mission-critical environments.– Sona SPEED General Manager Bart Korff

Reflecting rising demand for lightweight, high-strength structures used in aircraft, satellites, and launch systems, Sona SPEED is strengthening its advanced forming and structural assembly capabilities, according to General Manager Bart Korff.

“We are expanding our metal forming and structural assembly capabilities to support next-generation aircraft, satellite, and launch vehicle programs,” says Mr. Korff. “Quintus Technologies brings proven expertise in high-pressure forming solutions that meet the stringent standards required for aerospace applications. Their technology enables us to deliver consistent quality, performance, and reliability to customers operating in mission-critical environments.”

The investment reflects broader industry trends toward lighter, stronger materials and faster development cycles across aerospace, defense, and high-performance industrial sectors. Advanced forming technologies such as the Flexform process enable manufacturers to reduce tooling complexity, improve structural performance, and accelerate product development timelines.

Sona SPEED selected the Flexform press model QFC 1×3-800, capable of applying up to 800 bar of forming pressure across a 1000 mm × 3000 mm work area. This performance is enabled by Quintus’ proven wire-winding pre-stress technology, which allows consistent pressure distribution across large forming surfaces.

“Flexform is a versatile solution for manufacturing complex sheet metal components, particularly in industries where precision, speed, and cost control are essential for maintaining global competitiveness,” explains Peter Henning, Chief Commercial Officer, Quintus Technologies.

Designed for both prototyping and low-volume production, the Flexform process offers significant advantages compared with conventional rubber pad pressing and mechanical stamping. High-pressure forming reduces tooling complexity, eliminates secondary process steps, and improves fabrication productivity. Multiple forming tools can be used in a single operation, enabling faster transitions from design to production. High-cycle systems can produce up to 120 parts per hour, supporting rapid response to customer requirements.

The user-friendly press includes advanced features such as equipment serviceability, remote system control, and a high degree of self-diagnostics. It is also equipped with state-of-the-art high pressure hydraulics and a semi-automatic service system for quick and easy service of the unique Quintus flexible rubber diaphragm.

“This investment completes Sona SPEED’s aerospace offering by enabling us to manufacture high-integrity, near-net-shape components with enhanced mechanical properties. The Quintus press integrates seamlessly into our production line, allowing the delivery of flight-critical parts with reduced lead times and improved material performance – essential for aerospace and space missions,” notes Mr. Korff.

To support long-term operational reliability, Sona SPEED has chosen to participate in the Quintus® Care Program, a customized service solution that ensures operational reliability, maximum performance, controlled annual costs, and long-term partnership.

The program includes forming process and tool design support, access to Quintus Application Centers, prioritized technical assistance, and reliable availability of spare and wear parts. It also provides annual press inspections, operator training, and personnel recertification to maintain high levels of technical competence and production readiness.

“The added value of the high pressure process allows Sona SPEED to meet the quality, volume, and cost demands for sheet metal parts in major industrial sectors across the globe,” comments Johan Hjärne, CEO of Quintus Technologies. “We are pleased to be a strategic partner as they scale operations, invest in advanced manufacturing technologies, and enhance their engineering capabilities.”

The press will be installed in Sona SPEED’s 100,000-square-foot advanced manufacturing facility on the outskirts of Bengaluru (Bangalore), India in mid-December 2026.

About Quintus Technologies

Quintus Technologies is the global leader in high pressure technology. The company designs, manufactures, installs, and supports high pressure systems in four main areas: densification of advanced materials; sheet metal forming; battery processing; and high pressure processing for food and beverage innovation, safety, and shelf life. Quintus has delivered approximately 1900 systems to customers within industries such as energy, medical implants, space, aerospace, automotive, and food processing. The company is headquartered in Västerås, Sweden, with a presence in 45 countries worldwide. For more information, visit Quintus Technologies.

About Sona SPEED

Part of the century-old Sona Group, a premier business group in India, Sona Special Power Electronics & Electric Drives (Sona SPEED) was established in 2003 as an R&D division specializing in cutting-edge mechatronics manufacturing solutions. The company provides a comprehensive range of metal treatment solutions tailored to the specific needs of a worldwide client base across industries like aerospace, defense, heavy equipment, medical wearables, space, marine, industrial, automotive, and more. Sona SPEED’s unwavering commitment to precision and quality in metal treatments is reflected in state-of-the-art facilities and advanced technology that ensure the delivery of products that excel in performance and durability, thus meeting highest standards required for the most sophisticated and mission-critical applications. To know more, go to Sona SPEED.

Media Contact

Peter Henning, Quintus Technologies, 46 736 20 24 49, peter.henning@quintusteam.com, quintustechnologies.com

View original content to download multimedia:https://www.prweb.com/releases/quintus-flexform-press-enables-sona-speed-to-deliver-flight-critical-aerospace-components-faster-302749534.html

SOURCE Quintus Technologies

Continue Reading

Technology

Hannover Messe 2026: Zoomlion Debuts Robot Ops, Showcasing Industrial AI and Intelligent Manufacturing Capabilities

Published

5 minutes ago

on

April 22, 2026

By

HANNOVER, Germany, April 22, 2026 /CNW/ — Zoomlion Heavy Industry Science & Technology Co., Ltd. (“Zoomlion” or “the Company”; 1157.HK) has made the global debut of its embodied intelligence operating system, Robot Ops, at Hannover Messe 2026, taking place from April 20 to 24. At the event, Zoomlion is showcasing the robot operating system for industrial applications, along with its industrial AI and intelligent manufacturing (IM) solutions. Through live demonstrations and themed presentations, Zoomlion is highlighting its latest advances in embodied intelligence development platforms and IM practices.

Built for the Software 3.0 era, Robot Ops is a professional embodied intelligence development platform centered on the engineering concept of “Data, Software, and Agents.” It integrates DevOps, DataOps, and AgentOps into a full-stack, engineering-grade solution, enabling coordinated development across software, data, and intelligent agents.

The platform comprises four modules: basic tools, imitation learning, reinforcement learning, and task orchestration, enabling full-lifecycle management from data collection and model training to simulation verification, application development, and deployment maintenance. Designed to be ready to use with a low barrier to adoption, Robot Ops improves closed‑loop iteration efficiency by over 50%.

It directly addresses four key industry challenges: high technical barriers, scenario migration difficulty, data bottlenecks, and lack of lifecycle management. By providing a standardized, replicable engineering path for large‑scale deployment, Robot Ops can be widely adapted to humanoid robots, industrial robots, construction machinery, and autonomous driving. As one platform empowering multiple industries, it supports a more scalable and standardized approach to embodied intelligence development.

At Hannover Messe 2026, Zoomlion is presenting live demonstrations under the unified scheduling of Robot Ops, in which a wheeled humanoid robot and a logistics mobile robot collaborate on a logistics-sorting scenario, while the first-generation mass-produced humanoid robot Z1 performs a dance routine and dynamic motion-control demonstration. The multi-robot collaborative demonstration shows how Robot Ops connects algorithms, task orchestration, and on-site execution.

Zoomlion is also presenting its Industry 5.0 IM solutions, including insights into Zoomlion Smart Industrial City. The showcase highlights how digital technologies such as intelligent scheduling, industrial AI, digital twins, and end-to-end intelligent logistics are integrated into manufacturing processes.

Zoomlion is exhibiting at Booth D76 in Hall 15 and Booth D70 in Hall 11, the China Pavilion. The Company is also co-exhibiting with Amazon Web Services (AWS) and participating in the China Pavilion’s “Invest in China” launch ceremony.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hannover-messe-2026-zoomlion-debuts-robot-ops-showcasing-industrial-ai-and-intelligent-manufacturing-capabilities-302749747.html

SOURCE Zoomlion

Continue Reading

Technology

Realm Raises $4.5M to Bring the ‘Cursor Moment’ to Enterprise Sales

Published

5 minutes ago

on

April 22, 2026

By

HELSINKI, April 22, 2026 /PRNewswire/ — Realm has raised a $4.5 million Seed round to speed up enterprise sales cycles. Its platform gives AI the structured context needed to automate deal-defining materials like RFP responses. The round was led by Frontline Ventures, with participation from HubSpot Ventures, Slack Co-founder Cal Henderson and Deel Co-founder Alex Bouaziz.

Realm CEO Mikko Mäntylä believes revenue work is next to undergo the agentic revolution that has already transformed software development.

“Tools like Cursor and Claude Code have fundamentally changed programming. Developers now manage fleets of agents, often running five to ten simultaneous tasks in different terminal windows,” Mäntylä says. “The best revenue teams are starting to replicate this approach, offloading RFP responses, security questionnaires, and other customer-facing materials to AI.”

However, the shift is still held back by a fundamental constraint. Unlike in software development, where the codebase provides structured context for AI, revenue teams work with fragmented systems and unstructured data. Critical information, such as why a deal was won, has to be pieced together from subtle, scattered signals.

Realm solves this by turning raw information into a structured representation of a company’s market, products, pipeline, and strategies. This purpose-built context graph mirrors how human sellers are onboarded and gives agents the foundation they need to contribute effectively.

“Our customers use Realm to draft their most important deliverables, from multi-million dollar bids to business cases that will make or break months of work,” Mäntylä says. “Typically, 70-80% of Realm’s work is approved as-is. Any edits feedback into Realm’s context, creating a compounding record that everyone in the organisation benefits from.”

That institutional memory extends beyond Realm’s own application. The platform integrates with Slack, CRMs, and AI assistants like Claude and ChatGPT, allowing teams to leverage Realm’s context and agents wherever they already work.

“The GTM stack has been built to record and report on what has already happened,” says George Radford from Frontline Ventures. “The emerging paradigm is tools that actually do the work, and Realm is building at the forefront of this shift. The team’s exceptional execution velocity and the rate at which customers are expanding usage convinced us Realm is the right team to back.”

The company will use the fresh funding to triple its team by the end of the year and accelerate its entry into the US.

About Realm

Realm builds a structured understanding of a company’s go-to-market and turns it into execution. As a result, work like RFPs, security reviews, and deal coordination happens in the background, not at the expense of time with buyers. Founded in 2023 by former Slush leaders Mikko Mäntylä and Miika Huttunen alongside Johan Jern, Realm is headquartered in Helsinki, Finland. Realm’s customers include Visma, Aiven, and Hostaway. Learn more: https://www.withrealm.com/ 

About Frontline Ventures

Frontline Ventures backs the most ambitious tech companies across the US and Europe, and positions them to win the transatlantic market. Frontline Seed backs European Seed startups when early US traction is critical to hyperscale. Frontline Growth backs US scaleups at Series B-D when European revenues are essential to IPO-readiness. Frontline Ventures’ portfolio includes companies like Navan, Lattice, and Vanta. Learn more: https://frontline.vc/ 

About HubSpot Ventures

HubSpot Ventures partners with ambitious entrepreneurs who are redefining how businesses grow and operate. The fund backs early- and growth-stage software companies building products that deliver unique value to HubSpot’s customer base, with a mission to help millions of organizations grow better. HubSpot Ventures’ portfolio includes companies like Clay, ElevenLabs, and Lovable. Learn more: https://www.hubspot.com/ventures. 

Media Contact
Mikko Mäntylä
CEO & Co-founder
mikko@withrealm.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/realm-technologies-oy/r/realm-raises–4-5m-to-bring-the–cursor-moment–to-enterprise-sales,c4338044

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/realm-raises-4-5m-to-bring-the-cursor-moment-to-enterprise-sales-302750015.html

SOURCE Realm Technologies Oy

Continue Reading

Trending